Fabino Enterprises Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003600,
    "name": "Fabino Enter",
    "stock_name": "Fabino Enter",
    "full_name": "Fabino Enterprises Ltd",
    "name_url": "stocks-analysis/fabino-enter",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "20.75",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "20.75",
    "mcapval": "5.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 543444,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0DRT01018",
    "curr_date": "Dec 18",
    "curr_time": "",
    "bse_nse_vol": 3000,
    "exc_status": "Active",
    "traded_date": "Dec 18, 2025",
    "traded_date_str": "2025 12 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/fabino-enter-1003600-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Fabino Enter?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-fabino-enter-3699747",
        "imagepath": "",
        "date": "2025-11-13 23:48:45",
        "description": "Answer:\nThe historical performance of Fabino Enter shows a consistent trend in its financial metrics over the past three years.\n\nBreakdown:\nFabino Enter's share capital has remained stable at Rs 2.10 crore from March 2023 to March 2025. Total reserves have shown a gradual increase, rising from Rs 2.01 crore in March 2023 to Rs 2.10 crore in March 2025. Shareholder's funds also increased slightly, from Rs 4.11 crore in March 2023 to Rs 4.20 crore in March 2025. Long-term borrowings have significantly increased, moving from Rs 0.41 crore in March 2023 to Rs 1.79 crore in March 2025, primarily due to an increase in unsecured loans. Total liabilities have risen sharply from Rs 5.00 crore in March 2023 to Rs 17.65 crore in March 2025, reflecting higher trade payables, which increased from Rs 0.37 crore to Rs 11.42 crore over the same period. Total assets have also grown, from Rs 5.00 crore in March 2023 to Rs 17..."
      },
      {
        "title": "When is the next results date for Fabino Enter?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-fabino-enter-3691261",
        "imagepath": "",
        "date": "2025-11-11 23:20:32",
        "description": "The next results date for Fabino Enter is scheduled for 13 November 2025...."
      },
      {
        "title": "Is Fabino Enter overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-fabino-enter-overvalued-or-undervalued-3605685",
        "imagepath": "",
        "date": "2025-10-09 08:07:03",
        "description": "As of 8 October 2025, the valuation grade for Fabino Enter has moved from risky to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 4.83, an EV to EBIT of 6.22, and a ROE of 3.03%. In comparison to its peers, Fabino Enter's PE ratio is significantly lower than Sun Pharma's 34.13 and Divi's Lab's 70.37, indicating that it is trading at a discount relative to these competitors despite its high valuation grade.\n\nFabino Enter's financial performance has been disappointing, as evidenced by a year-to-date stock return of -30.09%, contrasting sharply with the Sensex's positive return of 4.65% over the same period. This underperformance, combined with its very expensive valuation grade and low profitability ratios, further supports the conclusion that the company is overvalued in the current market environment...."
      },
      {
        "title": "Is Fabino Enter overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-fabino-enter-overvalued-or-undervalued-3563332",
        "imagepath": "",
        "date": "2025-09-24 08:08:12",
        "description": "As of 23 September 2025, the valuation grade for Fabino Enter has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 5.09, an EV to EBIT of 6.49, and a Price to Book Value of 1.19, which suggest that the stock is trading at a premium compared to its earnings and book value.\n\nIn comparison to its peers, Fabino Enter's valuation appears high, especially when looking at companies like Sun Pharma with a PE ratio of 34.11 and Divi's Lab at 69.64, both of which are categorized as expensive to very expensive. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -26.29% compared to the Sensex's positive return of 5.07%. This underperformance further reinforces the conclusion that Fabino Enter is ..."
      }
    ],
    "total": 24,
    "sid": "1003600",
    "stock_news_url": "https://www.marketsmojo.com/news/fabino-enterprises-1003600"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2025",
      "datetime": "13-Nov-2025",
      "details": "1. The Unaudited Standalone Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2025 together with Statement of Assets and Liabilities and Statement of Cash Flow. 2. The Unaudited Consolidated Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30 2025 together with Statement of Assets and Liabilities and Statement of Cash Flow.",
      "source": "BSE"
    },
    {
      "caption": "Results- Financial Results For The Half Year Ended September 30 2025",
      "datetime": "13-Nov-2025",
      "details": "Results- Financial results for the Half Year ended September 30 2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone And Consolidated) For Half Year Ended September 30 2025",
      "datetime": "10-Nov-2025",
      "details": "Fabino Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve the Unaudited Financial Results (Standalone and Consolidated) for Half Year Ended September 30 2025 thereon and any other business with permission of Chair",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Fabino Enter?

2025-11-13 23:48:45

Answer: The historical performance of Fabino Enter shows a consistent trend in its financial metrics over the past three years. Breakdown: Fabino Enter's share capital has remained stable at Rs 2.10 crore from March 2023 to March 2025. Total reserves have shown a gradual increase, rising from Rs 2.01 crore in March 2023 to Rs 2.10 crore in March 2025. Shareholder's funds also increased slightly, from Rs 4.11 crore in March 2023 to Rs 4.20 crore in March 2025. Long-term borrowings have significantly increased, moving from Rs 0.41 crore in March 2023 to Rs 1.79 crore in March 2025, primarily due to an increase in unsecured loans. Total liabilities have risen sharply from Rs 5.00 crore in March 2023 to Rs 17.65 crore in March 2025, reflecting higher trade payables, which increased from Rs 0.37 crore to Rs 11.42 crore over the same period. Total assets have also grown, from Rs 5.00 crore in March 2023 to Rs 17...

When is the next results date for Fabino Enter?

2025-11-11 23:20:32

The next results date for Fabino Enter is scheduled for 13 November 2025....

Is Fabino Enter overvalued or undervalued?

2025-10-09 08:07:03

As of 8 October 2025, the valuation grade for Fabino Enter has moved from risky to very expensive. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 4.83, an EV to EBIT of 6.22, and a ROE of 3.03%. In comparison to its peers, Fabino Enter's PE ratio is significantly lower than Sun Pharma's 34.13 and Divi's Lab's 70.37, indicating that it is trading at a discount relative to these competitors despite its high valuation grade. Fabino Enter's financial performance has been disappointing, as evidenced by a year-to-date stock return of -30.09%, contrasting sharply with the Sensex's positive return of 4.65% over the same period. This underperformance, combined with its very expensive valuation grade and low profitability ratios, further supports the conclusion that the company is overvalued in the current market environment....

Is Fabino Enter overvalued or undervalued?

2025-09-24 08:08:12

As of 23 September 2025, the valuation grade for Fabino Enter has moved from expensive to very expensive, indicating a significant shift in its perceived market value. The company is currently considered overvalued based on its financial metrics. Key ratios include a PE ratio of 5.09, an EV to EBIT of 6.49, and a Price to Book Value of 1.19, which suggest that the stock is trading at a premium compared to its earnings and book value. In comparison to its peers, Fabino Enter's valuation appears high, especially when looking at companies like Sun Pharma with a PE ratio of 34.11 and Divi's Lab at 69.64, both of which are categorized as expensive to very expensive. Additionally, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -26.29% compared to the Sensex's positive return of 5.07%. This underperformance further reinforces the conclusion that Fabino Enter is ...

View All News